Centhaquine (Centhaquin) 是一种具有研究出血性休克的潜力的试剂。Centhaquine 在出血模型中可以减少全身血管阻力。

Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of  haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models.

Solid

Centhaquine (Centhaquin) (intravenous injection, 0.01-1.0 mg/kg; intraduodenal administration 1.0-2.5 mg/kg) lowers the blood pressure and reduced the heart rate of anaesthetized and unanaesthetized (decerebrate) cat in a dose-dependent manner.
Centhaquine (Centhaquin) (intravertebral arterial injection; 5-10 μg) or by topical application to the exposed ventral surface of medulla or floor of the fourth ventricle causes hypotension and bradycardia as well as reduced the excitability of the vasomotor loci.
Centhaquine (Centhaquin;PMZ-2010) (intravenous administration; 0.015mg/kg) can attenuate the deleterious effects of catecholamines, improving both the macro- and microcirculation during CPR.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Srimal RC,et al. Pharmacological studies on 2-(2-(4-(3-methylphenyl)-1-piperazinyl)ethyl) quinoline (centhaquin). I. Hypotensive activity.Pharmacol Res. 1990 May-Jun;22(3):319-29.
[2]. Papalexopoulou K, et al. Centhaquin Effects in a Swine Model of Ventricular Fibrillation: Centhaquin and Cardiac Arrest.Heart Lung Circ. 2017 Aug;26(8):856-863.

In Vitro: DMSO : 62.5 mg/mL (188.57 mM; Need ultrasonic)配制储备液